CD274 and non-small cell lung carcinoma: According to the Food and Drug Administration (FDA) and European Medicines Agency (EMA), PD-L1 high expression with the expression on TCs no less than 50% or ICs no less than 10% is one of the basis to choose ICIs as the first line in advanced NSCLC patients (10, 11).